Best Practices, LLC Report Reveals Pharma Launch Resourcing Benchmarks for Competitive Market Success
CHAPEL HILL, N.C., June 6, 2025/ -- Biopharmaceutical companies continue to face unprecedented challenges when launching new therapies—tight market windows, evolving digital strategies, and shifting stakeholder expectations. To help commercial teams optimize their investment and resourcing strategies, Best Practices, LLC has released a new benchmarking report, "Achieving Launch Market Leadership: Resourcing the Next Generation of Blockbusters."
Based on data from 61 product launches across 48 leading pharma and biotech companies, the report offers rich insights into how organizations are allocating resources across commercial, medical, and patient access activities—both before and during launch. With launch investments rising steadily post-COVID, the study identifies how market archetype, Peak Year Sales Forecast (PYSF), and competitive context shape resource planning decisions.
Key focus areas include:
- Year-by-year resource allocation strategies
- PYSF-based investment benchmarks
- Commercial vs. medical activity budgeting
- Market-entry archetypes and their impact on resourcing
- Post-COVID shifts in launch investments
Select findings include:
- Upstart products entering crowded markets spend 20% more at launch than in all previous years combined.
- Resourcing becomes more balanced at launch, with continued prioritization of sales force prep and patient education.
This report is a critical resource for executives seeking to streamline operations and elevate the value of their scientific and access functions..
For a deeper dive, download the complimentary report summary here: https://www.best-in-class.com/rw469.htm
Pressed for time? Watch the short video summary below to uncover the key findings and recommendations from the study: